Literature DB >> 23023401

Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits.

Philippe Daull1, Frédéric Lallemand, Betty Philips, Grégory Lambert, Ronald Buggage, Jean-Sébastien Garrigue.   

Abstract

PURPOSE: The aim of this study was to compare the ocular and systemic distribution of cyclosporine A (CsA) in rabbits after the instillation of preservative-free CsA cationic and anionic emulsions.
METHODS: For the single-dose pharmacokinetic (PK) study, rabbits were instilled with 50 μL of the test material. For the multiple-dose PK study, rabbits were instilled twice daily with Restasis or once daily with NOVA22007 for 10 days. At each time point, the cornea, conjunctiva, and whole blood were harvested for CsA quantification. Ocular and systemic distribution were determined after 4 times daily instillations with 50 μL of 3H-CsA cationic and anionic emulsions for 7 days. Restasis was used as a reference in all studies.
RESULTS: Single-dose PK data demonstrated that NOVA22007 0.1% and 0.05% delivered higher CsA concentrations to the cornea than Restasis [concentration maximum (C max): 2692, 1372, and 748 ng/g, respectively] and have a better exposition (area under the curve). Conjunctival Cmax values were 1914, 696, and 849 ng/g and area under the curve values were 3984, 2796, and 2515 ng/g · h, for either dose of the cationic emulsions and Restasis, respectively. The multiple-dose PK and the 3H-CsA distribution data demonstrated that the systemic distribution after repeated instillations was low and comparable for all emulsions.
CONCLUSIONS: These data demonstrate that the CsA cationic emulsions were more effective than Restasis at delivering CsA to target tissues, thus confirming the potential advantage of cationic emulsions over anionic emulsions as vehicle for ocular drug delivery for the treatment of ocular surface diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23023401     DOI: 10.1097/ICO.0b013e31825e83f4

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  13 in total

Review 1.  Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials.

Authors:  Bridgitte Shen Lee; Melissa Toyos; Paul Karpecki; Jessica Schiffbauer; John Sheppard
Journal:  Ophthalmol Ther       Date:  2022-05-24

Review 2.  Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

3.  Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.

Authors:  Frederic Lallemand; Philippe Daull; Simon Benita; Ronald Buggage; Jean-Sebastien Garrigue
Journal:  J Drug Deliv       Date:  2012-02-27

Review 4.  Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery.

Authors:  Philippe Daull; Frédéric Lallemand; Jean-Sébastien Garrigue
Journal:  J Pharm Pharmacol       Date:  2014-04       Impact factor: 3.765

5.  Surface Chemistry Interactions of Cationorm with Films by Human Meibum and Tear Film Compounds.

Authors:  Georgi As Georgiev; Norihiko Yokoi; Yana Nencheva; Nikola Peev; Philippe Daull
Journal:  Int J Mol Sci       Date:  2017-07-18       Impact factor: 5.923

6.  One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.

Authors:  Christophe Baudouin; Maite Sainz de la Maza; Mourad Amrane; Jean-Sébastien Garrigue; Dahlia Ismail; Francisco C Figueiredo; Andrea Leonardi
Journal:  Eur J Ophthalmol       Date:  2017-11-08       Impact factor: 2.597

7.  Effect of a Cationic Surfactant on Microemulsion Globules and Drug Release from Hydrogel Contact Lenses.

Authors:  Cesar Torres-Luna; Naiping Hu; Abdollah Koolivand; Xin Fan; Yuli Zhu; Roman Domszy; Jeff Yang; Arthur Yang; Nam Sun Wang
Journal:  Pharmaceutics       Date:  2019-06-06       Impact factor: 6.321

8.  Polymeric Micelles for the Enhanced Deposition of Hydrophobic Drugs into Ocular Tissues, without Plasma Exposure.

Authors:  Ijeoma F Uchegbu; Jan Breznikar; Alessandra Zaffalon; Uche Odunze; Andreas G Schätzlein
Journal:  Pharmaceutics       Date:  2021-05-18       Impact factor: 6.321

Review 9.  Novel formulations for antimicrobial peptides.

Authors:  Ana Maria Carmona-Ribeiro; Letícia Dias de Melo Carrasco
Journal:  Int J Mol Sci       Date:  2014-10-09       Impact factor: 5.923

10.  Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.

Authors:  Andrea Leonardi; Elisabeth M Messmer; Marc Labetoulle; Mourad Amrane; Jean-Sébastien Garrigue; Dahlia Ismail; Maite Sainz-de-la-Maza; Francisco C Figueiredo; Christophe Baudouin
Journal:  Br J Ophthalmol       Date:  2018-03-15       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.